Breast cancer claims approximately 670,000 lives annually. According to data from the World Health Organization (WHO), breast cancer was the most prevalent cancer among women in 157 out of 185 countries in 2022, with over 2 million women being diagnosed each year. This highlights the importance of early detection and the development of targeted therapies for cancer cells. The US Food and Drug Administration (FDA) has approved the use of Kisqali, also known as ribociclib, in combination with hormone therapy for early-stage breast cancer treatment. This approval is particularly beneficial for patients concerned about cancer recurrence. The FDA endorsed ribociclib for use with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. The drug works by inhibiting specific proteins, CDK4 and CDK6, which are responsible for cancer cell growth. Kisqali will be administered orally, typically for three weeks followed by a one-week break, and continued for a duration of three years. It can be taken with or without food, with a recommended daily dose of 400 mg.Kisqali: Side Effects

Common side effects of Kisqali medication include low white blood cell count, also known as neutropenia. Neutropenia refers to decreased levels of neutrophils in the blood, which are crucial for fighting infections. Additionally, Kisqali can also cause liver-related problems and interstitial lung disease/pneumonitis.

Breast Cancer: Warning Signs that Should Not Be Overlooked